Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Equities research analysts at StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Get Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Not all weight loss programs are made equal—to reach a healthy, sustainable weight, personalized programs offer the best ...

Lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without disclosing safety and risk information.